Respicardia, Inc.
9
0
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
22.2%
2 terminated/withdrawn out of 9 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
67%
4 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Janus Feasibility Study
Role: lead
remedē System Therapy Study
Role: lead
Post Approval Study of the remedē System
Role: lead
Respicardia, Inc. Pivotal Trial of the remedē System
Role: lead
The remedē® System for the Treatment of Central Sleep Apnea in Daily Practice
Role: collaborator
Chronic Evaluation of Respicardia Therapy
Role: lead
Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea
Role: lead
Feasibility Study to Determine the Effects of Phrenic Nerve Stimulation in Patients With Periodic Breathing
Role: lead
Identification of the Pericardiophrenic Vein During Cardiac Device Implant Procedures to Prevent Extracardiac Stimulation
Role: lead
All 9 trials loaded